ArticleCurrent health sciences journal
Determinants of Background Parenchymal Enhancement on breast MRI.
Article in Current health sciences journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background parenchymal enhancement (BPE) on breast magnetic resonance imaging (MRI) is a functional marker influenced by hormonal and vascular factors. It has been linked to breast cancer in prior studies, but shows wide variability across patient and clinical characteristics. Understanding its patterns is essential, yet data from Eastern European populations remain scarce. We retrospectively analyzed 353 women who underwent breast MRI at our center between January 2019 and January 2025. BPE and fibroglandular tissue (FGT) were classified according to Breast Imaging Reporting and Data System (BI-RADS). Patient age, menopausal status, body mass index (BMI), and tamoxifen use were recorded. Associations between BPE and clinical variables were evaluated with chi-square and Kruskal-Wallis tests. BPE decreased with age and was substantially lower in postmenopausal women (p<0.001). Women with heterogeneous (C) or extreme (D) FGT showed higher levels of BPE, reflecting the predominance of dense parenchyma among younger patients. BMI showed a modest but significant association (p=0.042), with overweight and obese women relatively more represented among moderate or marked enhancement. All patients on tamoxifen (n=25) displayed minimal BPE (p<0.001). In conclusion, BPE was strongly associated with age, menopausal status, FGT, and tamoxifen therapy in this cohort. These findings confirm its role as a hormonally driven imaging feature and underline the need to interpret BPE together with patient characteristics in daily practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.